Assessment of the effect of a single oral dose of telithromycin on sotalol-induced QT interval prolongation in healthy women

British Journal of Clinical Pharmacology

Volumn 60, Issue 2, 2005, Pages 120-127

  Démolis, Jean Louis ^a   Strabach, Soraya ^a   Vacheron, Françoise ^b   Funck Brentano, Christian ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b SANOFI   (France)

Author keywords

Drug Interactions; Electrocardiography; Long QT Syndrome; QT interval; Sotalol; Telithromycin

Indexed keywords

SOTALOL; TELITHROMYCIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG POTENTIATION; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; KETOLIDES; LONG QT SYNDROME; SOTALOL; VENTRICULAR FUNCTION;

EID: 23044439333     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02395.x     Document Type: Article

References (24)

1. Balfour JA, Figgitt DP. Telithromycin. Drugs 2001; 61: 815-29.
2. Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 1989; 63: 867-9.
3. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002; 25: 263-86.
4. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shar R. The potential for QT prolongation and pro-arrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47: 219-33.
5. Démolis JL, Charransol A, Funck-Brentano C, Jaillon P. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol 1996; 41: 499-503.
6. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-5.
7. Démolis JL, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000; 68: 658-66.
8. Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995; 9: 3010-6.
9. Tschida SJ, Guay DR, Straka RJ, Hoey LL, Johanning R, Vance-Bryan K. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy 1996; 16: 663-74.
10. Démolis JL, Vacheron F, Cardus S, Funck-Brentano C. Effect of a single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther 2003; 73: 242-52.
11. Edvardsson N, Hirsch I, Emanuelsson H, Ponten J, Olsson SB. Sotalol-induced delayed ventricular repolarization in man. Eur Heart J 1980; 1: 335-43.
12. Funck-Brentano C, Kibleur Y, Le Coz F, Poirier JM, Mallet A, Jaillon P. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. Circulation 1991; 83: 536-45.
13. Bazett HC An analysis of the time-relations of electrocardiograms. Heart 1920; 70: 353-70.
14. Fridericia LS. Die Sytoledauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 1920; 53: 522-34.
15. Le Coz F, Funck-Brentano C, Poirier JM, Kibleur Y, Mazoit FX, Jaillon P. Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers. Clin Pharmacol Ther 1992; 52: 417-26.
16. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. Jama 1993; 270: 2590-7.
17. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d, 1-sotalol. Circulation 1996; 94: 2535-41.
18. Stramba-Badiale M, Locati EH, Martinelli A, Courville J, Schwartz PJ. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holier recordings. Eur Heart J 1997; 18: 1000-6.
19. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 1998; 7: 547-57.
20. Lepeschkin E, Surawicz B. The measurement of the QT interval of the electrocardiogram. Circulation 1952; 6: 378-88.
21. Anttila M, Arstila M, Pfeffer M, Tikkanen R, Vallinkoski V, Sundquist H. Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol (Copenh) 1976; 39: 118-28.
22. Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol 1997; 43: 269-72.
23. Hanyok JJ. Clinical pharmacokinetics of sotalol. Am J Cardiol 1993; 72: 19A-26A.
24. Zanetti LA. Sotalol: a new class III antiarrhythmic agent. Clin Pharm 1993; 12: 883-91.